Priority aged care support for Australians with MND - Australian Government Department of Health, Disability and Ageing

Type 2 DiabetesSurvodutide Reduced Body Weight for Patients With Type 2 Diabetes and ObesityType 2 DiabetesSurvodutide Reduced Body Weight for Patients With Type 2 Diabetes and ObesityPublished: October 21, 2026The SYNCHRONIZE-2 trial is a multinational, double-blind phase 3 trial conducted by Sean Wharton, MD, PharmD, of McMaster University in Hamilton, Ontario, Canada, and colleagues to evaluate the investigational glucagon receptor–glucagon-like peptide-1 receptor dual agonist survodutide. For patients with both type 2 diabetes and obesity, Dr. Wharton and colleagues wrote, “Weight management may be the most effective therapy for type 2 diabetes.”This trial enrolled 752 patients with type 2 diabetes and a BMI of at least 27. Patients were randomly assigned on a 1-to-1-to-1 basis to receive 3.6 mg of survodutide (n=250), 6.0 mg of survodutide (n=251), or placebo (n = 251) by once-weekly injection. The primary end points were percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76. The mean weight change at week 76 (treatment-regimen estimand) was –8.2% in the 3.6-mg group, –9.8% in the 6.0-mg group, and –3.9% in the placebo group.